ArticleInternational journal of clinical oncology2026
Deubiquitinases as prognostic biomarker and potential drug target for gynecological cancers.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo develop Deubiquitinase-Associated Signatures (DAS) to predict the prognosis of gynecological cancer patients.
methodsUsing a Cox-Lasso regression model, we have developed deubiquitinase-associated signatures for Cervical, Ovarian, and Uterine cancers. Developed DAS were validated in TCGA and GEO datasets. Survival analysis was carried out to know the effect of factors Like menopausal stage and grade on DAS. The Survival prediction accuracy of DAS was analyzed using ROC curves. Immune infiltration scores of 22 immune subtypes were explored using the CIBERSORT package in risk groups classified by DAS. Further, to target the unfavorable deubiquitinases (DUBs), compounds were identified using CMap database.
resultsThree DAS were developed for Cervical, Ovarian, and Uterine cancer types. DAS was able to predict Survival and classify patients into two groups in TCGA and GEO datasets. DAS is an independent predictor of Survival irrespective of tumor grade and menopausal stage. DAS, along with the clinical features, improves the accuracy of predictions. CIBERSORT analysis has shown that immune cell infiltration is associated with risk groups divided by DAS. Using CMap, 52 compounds were identified to target unfavorable DUBs.
conclusionDAS is a good predictor of survival, and targeting unfavorable DUBs may reduce tumor progression in gynecological cancers.
Indexed as
Identifiers
41201663What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.